Point72 Asia (Singapore) Pte. Ltd. Actinium Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 10,295 shares of ATNM stock, worth $13,383. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,295
Previous 21,042
51.07%
Holding current value
$13,383
Previous $29.5 Million
44.08%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
6.8MCall Options Held
42.3KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny625KShares$812,1060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...